Mycophenolate mofetil: risks of miscarriage and birth defects. Patient guide

Similar documents
Annex III. Amendments to relevant sections of the Product Information

VALPROATE. (Epilim, Depakote ) Patient Information Booklet

Valproate. (Epilim, Depakote, Convulex, Episenta, Epival, Kentlim, Orlept, Sodium Valproate, Syonell & Valpal)

Package leaflet: Information for the user

Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants:

Annex III. Amendments to relevant sections of the summary of product characteristics and package leaflets

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

Package leaflet: Information for the patient. Destolit 150 mg tablets Ursodeoxycholic acid

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

PATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate

Package leaflet: Information for the patient

In the Republic of Ireland, side effects can be reported online at or directly to the HPRA by calling (01)

Package leaflet: Information for the user. Ursodeoxycholic Acid Tablets 150mg (Ursodeoxycholic acid)

Mycophenolate treatment for respiratory conditions. Information for patients Respiratory Medicine - Asthma

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

Package leaflet: Information for the patient

Pregnancy, birth and postnatal information for women who have epilepsy

Package leaflet: Information for the user. Ursodeoxycholic Acid Capsules 250mg (Ursodeoxycholic acid)

LEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam

Aciclovir Apotex 800 mg tabletten RVG Package leaflet: Information for the user Aciclovir Apotex 800 mg tabletten Aciclovir

PLEASE READ Important Patient Safety Information Approved by HPRA

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

JINARC (tolvaptan) Patient/carer education brochure

Aciclovir Apotex 200 mg tabletten RVG Package leaflet: Information for the user Aciclovir Apotex 200 mg tabletten Aciclovir

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

Package leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel

Package leaflet: Information for the patient. Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon

PROSCAR 5mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT PROSCAR IS AND WHAT IS IT USED FOR

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Package leaflet: Information for the user. Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion atosiban

Package leaflet: Information for the user. Norditropin SimpleXx 5 mg/1.5 ml solution for injection in cartridge somatropin

PACKAGE LEAFLET: INFORMATION FOR THE USER. CO-AMOXICLAV TEVA 1000 mg/200 mg POWDER FOR SOLUTION FOR INJECTION/INFUSION INJECTION/INFUSION

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

Package leaflet: Information for the patient. Calcium Folinate 15 mg Tablets calcium folinate

Package leaflet: Information for the patient

AUGMENTIN is also used to prevent infection from major surgery.

Package leaflet: Information for the user. Tetrabenazine 25 mg tablets. tetrabenazine

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain

Package Leaflet: Information for the User

What are some things I need to know or do while I take

1. What Miacalcic is and what it is used for

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Are you protected against measles mumps and rubella?

PLEASE READ Important Patient Safety Information Approved by HPRA

Package leaflet: Information for the patient

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib

Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

Sexual Health and Contraception when you have Chronic Kidney Disease

Package leaflet: Information for the user. Compound Macrogol Oral Powder Sugar Free

PACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil

2 What you need to know before you use Beconase. Package Leaflet: Information for the user

Package leaflet: Information for the patient. Velphoro 500 mg chewable tablets Iron as sucroferric oxyhydroxide

Patient Guide. This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully.

Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

Package Leaflet: Information for the user Laxido Paediatric Plain 6.9 g, powder for oral solution

It is used to treat breast cancer in women after chang e of life. It may be g iven to you for other reasons. Talk with the doctor.

Abatacept Drug information. Abatacept is used to treat rheumatoid arthritis.

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

Drug information. Sarilumab SARILUMAB. is used to treat rheumatoid arthritis. Helpline

Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals

Package leaflet: Information for the user

FDA APPROVED MEDICATION GUIDE

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.

Information on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women.

Bonefos 400 mg capsules sodium clodronate

Imodium 1 mg/5 ml oral solution

Please note that this information leaflet is for men, there is a separate information leaflet for women.

1. What Ursofalk 250mg hard capsules are and what they are used for

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

Package leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone

Rheumatology Department Patient Information Leaflet. Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis.

It may be g iven to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug?

Acute Hepatitis B Fact Sheet

Important safety information to minimise the risk of immune-related adverse reactions

Package leaflet: Information for the user innohep 20,000 IU/ml tinzaparin sodium

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA. elagolix (as elagolix sodium) tablets

Randy J. EMPLICITI patient Ready to get started

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

Package leaflet: Information for the user. multibic potassium-free solution for haemodialysis/haemofiltration

PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Package Leaflet: Information for the user

Transcription:

Mycophenolate mofetil: risks of miscarriage and birth defects Patient guide Key points to remember Mycophenolate mofetil causes birth defects and miscarriages Follow the contraceptive advice given to you by your doctor to avoid accidental pregnancy if you are treated with products containing mycophenolate If you do not fully understand the information you have been given, ask your doctor to explain it again before you take mycophenolate mofetil Do NOT stop taking mycophenolate mofetil without talking to your doctor This medicine is only for you - do not give it to anyone else because it may be harmful to them If you are a woman who could become pregnant, you will need to have a pregnancy test before you start taking mycophenolate mofetil If you are treated with products containing mycophenolate and can become pregnant, your prescriber will: talk with you about the risks of mycophenolate mofetil for an unborn baby talk with you about how to avoid these risks with contraception (birth control) and pregnancy planning answer any questions you may have on this subject This guide will help you to remember the information you have discussed with your doctor. Keep it so that you can refer to it again. Also, read the package leaflet supplied with your medicine for full information on mycophenolate mofetil. Contents: 1. Is this information relevant to me? 2. What are the risks? 3. How likely is it that my unborn baby will be harmed? 4. What should I do? 1. Is this information relevant to me? The following people need to be particularly aware of the risks of mycophenolate mofetil for an unborn baby: pregnant women any woman who could become pregnant, including girls who have entered puberty and all women who have a womb and have not passed through the menopause Teva B.V. Swensweg 5, 2031GA Haarlem, Netherlands on behalf of Teva UK Limited Page 1 of 5

2. What are the risks? Mycophenolate has an increased risk of miscarriage or birth defects (problems that happen while a baby is developing in the mother's body). The exact reason why this happens is not clear but the risk is greater in pregnant patients taking mycophenolate than those taking other immunosuppressants (medicines that weaken the body s immune system) and much greater than the risk in the general population The birth defects that can occur include: abnormalities of the ears, eyes, face, fingers, kidneys or oesophagus (the part of the digestive tract connecting the mouth with the stomach) congenital heart diseases (that is, heart diseases present from birth) congenital disorders of the nervous system such as spina bifida (a condition where the backbone does not develop properly in an unborn baby) 3. How likely is it that my unborn baby will be harmed? If a pregnant woman is exposed to mycophenolate mofetil, there is a risk that it will cause a miscarriage or birth defects in her unborn baby (see above). Studies have shown that around half (45 to 49%) of all pregnancies in women taking mycophenolate mofetil end in miscarriage, compared with 12 to 33% in women taking other immunosuppressants and 15-20% in the general population. Around a quarter (23 to 27%) of babies born to women taking mycophenolate mofetil during pregnancy are born with birth defects, compared with 4 to 5% for women taking other immunosuppressants following transplantation, and 2 to 3% in the general population. Teva B.V. Swensweg 5, 2031GA Haarlem, Netherlands on behalf of Teva UK Limited Page 2 of 5

4. What should I do? Information for women and men is presented separately see overleaf for information for men and information for both men and women. Important information for women Because mycophenolate mofetil can cause miscarriage or birth defects: do not take mycophenolate mofetil if you are pregnant or might become pregnant unless there is no suitable alternative treatment you will need to have a pregnancy test before you start taking mycophenolate mofetil use effective contraception (birth control) while taking mycophenolate mofetil and for at least 6 weeks after your last dose talk to your doctor immediately if you think you could be pregnant do NOT stop taking mycophenolate mofetil without speaking to your doctor talk to your doctor if you want to become pregnant, or if you have any questions or concerns Pregnancy tests If you are capable of becoming pregnant, you will need to have a pregnancy test before starting treatment with mycophenolate mofetil. Your doctor will explain the type and timing of the pregnancy tests that need to be carried out before and during treatment with mycophenolate mofetil. Your doctor will recommend two blood or urine pregnancy tests; the second test should be carried out 8 to 10 days after the first one and immediately before you start taking mycophenolate mofetil. Your doctor might suggest repeating these tests at certain times (e.g. if there has been a gap in the use of effective contraception). Your doctor will discuss the results of all pregnancy tests with you. Contraception To make sure you do not become pregnant, use effective contraception (birth control) while you are taking mycophenolate mofetil and for at least 6 weeks after your last dose. If you have sex with a man, you must use one form of effective contraception, unless abstinence is the chosen method of contraception. Two complementary forms of contraception will reduce the risk of you becoming pregnant and are preferred. Your doctor will talk to you about different forms of contraception and help you decide what is best for you. If you think you might be pregnant If you think you might have become pregnant while taking mycophenolate mofetil, or within 6 weeks after your last dose, talk to your doctor immediately. It is very important that you do NOT stop taking mycophenolate mofetil without speaking to your doctor first. If you are a transplant patient, your transplant may be rejected if you stop taking mycophenolate mofetil. Your doctor will help you determine if you are pregnant, and will advise you what to do. Teva B.V. Swensweg 5, 2031GA Haarlem, Netherlands on behalf of Teva UK Limited Page 3 of 5

Important information for men Because mycophenolate mofetil can cause miscarriages and birth defects: it is recommended that you or your female partner uses reliable contraception while you are taking mycophenolate mofetil and for at least 90 days after your last dose talk to your doctor immediately if you think your partner might be pregnant do NOT stop taking mycophenolate mofetil without speaking to your doctor talk to your doctor about the risks if you intend to father a child, or if you have any questions or concerns Contraception The limited clinical evidence available does not indicate any increased risk of malformations or miscarriage if you take mycophenolate. However, a risk cannot be completely excluded. As a precaution, it is recommended that you or your female partner use reliable contraception while you are taking mycophenolate mofetil and for at least 90 days after your last dose. Do not donate sperm while taking mycophenolate mofetil and for at least 90 days after your last dose. If you think your partner might be pregnant If you think your partner might have become pregnant while you were taking mycophenolate mofetil, or within 90 days after your last dose, talk to your doctor. Your doctor will help to determine if your partner is pregnant, and will advise you both what to do. Important information for men and women If you want to have a baby Tell your doctor if you want to have a baby. It is very important that you do NOT stop taking mycophenolate mofetil without speaking to your doctor. Do not share your medicine This medicine has been prescribed for you only. Do not give it to other people. It may harm them, even if their symptoms are the same as yours. Return any unused medicine to your pharmacist at the end of treatment. Do not donate blood Do not donate blood while taking mycophenolate mofetil and for at least 6 weeks after your last dose. Your doctor s contact details If you have urgent questions concerning the pregnancy risks of mycophenolate mofetil, please contact your doctor at the following telephone numbers: During opening hours After closing Teva B.V. Swensweg 5, 2031GA Haarlem, Netherlands on behalf of Teva UK Limited Page 4 of 5

For further information, see the Package Leaflet. If you think you re having a side effect If you think you are experiencing any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please also report suspected side effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or to the Marketing Authorisation holder whose contact details are in the package leaflet. By reporting side effects you can help provide more information on the safety of this medicine. Teva B.V. Swensweg 5, 2031GA Haarlem, Netherlands on behalf of Teva UK Limited Page 5 of 5